Biocomposites Limited – Trademark Portfolio
Entity Type: 03
Biocomposites Limited holds 34 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 26 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 18 trademarks are registered and 3 are pending. Notable registered marks include BILOK, DRY26, GENEX, FXFADE, and FORTOSS. The owner is based in Staffordshire, ST1 SPQ.
Etruscan Street, Etruria, Stoke-on-Trent
Staffordshire, ST1 SPQ , GB
Showing of trademarks Trademarks
Trademark Classifications
Biocomposites Limited's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Biocomposites Limited have?
Biocomposites Limited has 34 U.S. trademarks filed with the USPTO. Of these, 18 registered, 3 pending, 4 abandoned, 7 cancelled.
What trademark classes does Biocomposites Limited file in?
Biocomposites Limited files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Biocomposites Limited's most well-known trademarks?
Biocomposites Limited's registered trademark portfolio includes well-known marks such as BILOK, DRY26, GENEX, FXFADE, and FORTOSS. These are among 18 currently registered trademarks in the portfolio.
What is Biocomposites Limited's trademark registration success rate?
Biocomposites Limited has a 62% trademark registration rate, with 18 out of 29 resolved applications resulting in successful registration. Currently, 3 applications are pending review.